4
Indication details
- Control Arm
- Standard chemotherapy
- Therapeutic Indication
- Treatment of patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or MBC who have been previously treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless unsuitable for these treatments
- Tumour Sub-type
- Breast Cancer
- Tumour Stage
- Locally advanced or metastatic
- Tumour Sub-Group
- HER2- g-BrCa+ve
- Trial Name
- OlympiAD
- NCT Number
- NCT02000622
- Trial Phase
- Phase III
Approval details
- FDA Approval
- FDA approval January 2018
- EMA Approval
- EMA approved February 2019
Primary Outcome(s)
- Primary Outcome(s)
- PFS
- Evaluated Outcome
- PFS
- Form(s)
- Form 2b
Outcome Data
- PFS Control
- 4.2 months
- PFS Gain
- 2.8 months
- PFS HR
- 0.58 (0.43-0.80)
- OS Control
- 17.1 months
- OS Gain
- 2.2 months
- OS HR
- 0.90 (0.66-1.23) Not significant (mature)
Adjustments
- QoL Comment
-
Delayed deterioration of QoL
- Toxicity Comment
-
Reduced toxicity
Final Score (after adjustments)
- Preliminary non-curative score
-
3
- Toxicity adjustment
- 1+
- Final non-curative score
-
4
Scorecard details
- ESMO-MCBS version
- ESMO-MCBS v1.1
- Scorecard ID
- 166
- Scorecard version
- 1
- Issue date
- 20.04.2020
- Last update
- 26.04.2024
Legend
Information about symbols, abbrevations and color codes
Red = negative
Green = positive
Grey = neutral
?
Grey + ? = neutral with pending data
- DFS
- Disease-Free Survival
- DoR
- Duration of Response
- EFS
- Event-Free Survival
- HR
- Hazard Ratio
- NEB
- No evaluable benefit
- NI
- Non-inferiority Study
- ORR
- Overall Response Rate
- OS
- Overall Surival
- pCR
- Pathological Complete Response/Remission
- PFS
- Progression-Free Survival
- QoL
- Quality of Life
- RFS
- Relapse-Free Survival
- RR
- Response Rate
QoL adjustments
Other adjustments*
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
QoL adjustments
Red = negative / deterioration
Green = positive / improvement
Other adjustments*
Red = negative / deterioration
Green = positive / improvement
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
* Other adjustments include:
- Long-term plateau in the survival curve
- Long-term plateau in the PFS curve
- Early stopping or crossover
- Only improved PFS mature data shows no OS advantage and no improved Qol.